Comparison of Botulinum Toxins A and B in the Aesthetic Treatment of Facial Rhytides

Sadick, Neil S.; Herman, Alysa R.

doi:10.1097/00042728-200304000-00004

Cited by 2 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BTX-A was approved by the United States Food and Drug Administration in 2002 for the treatment of glabellar wrinkles. 20 It is widely used for minimally invasive facial rejuvenation, and there are many commercial brands available. 21 BTX-B was initially approved by the Food and Drug Administration in 2000 for the treatment of cervical dystonia although it has also been widely used off label for cosmetic purposes.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review

Geoghegan

Rodrigues

Harrison

et al. 2022

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by suppurative infection, sinus tract, and abscess formation. International management guidelines are largely consensus-based. Botulinum toxin (BTX) has been widely used in the treatment of apocrine and eccrine gland disorders, such as hyperhidrosis, although the effectiveness of BTX in the treatment of HS remains unknown. The aim of this systematic review was to understand the published evidence of BTX safety and effectiveness in the management of HS. Methods: We conducted a PRISMA-compliant, prospectively registered (PROSPERO, CRD42021228732), systematic review. We devised bespoke search strategy and applied it to the Cochrane Central Register of Controlled Trials, Medline, Embase, and OpenGrey up until March 2022. We included all clinical studies that reported outcomes following BTX treatment in patients diagnosed with HS (both adult and pediatric). Results: A total of 4658 studies were identified, of which six met full inclusion criteria reporting data on 26 patients. The six identified studies included one randomized control trial, one case series, and four case studies. The one included randomized control trial demonstrated a significant reduction in the Dermatology Life Quality Index score at 3 months following treatment with BTX. Conclusions: The effectiveness and safety of BTX in the treatment of HS remain unknown. This systematic review identified a paucity of high-quality clinical data. Evidence of treatment effectiveness is likely to come from registry-based cohort studies using established core outcome sets in the first instance.

show abstract

Section: Methodsmentioning

confidence: 99%

“…21 BTX-B was initially approved by the Food and Drug Administration in 2000 for the treatment of cervical dystonia although it has also been widely used off label for cosmetic purposes. 20 We are interested in all BTX preparations and brands and will refer to them collectively as BTX throughout.…”

Section: Methodsmentioning

confidence: 99%

The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review

Geoghegan

Rodrigues

Harrison

et al. 2022

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

show abstract

“…[2][3][4][5] The heavy chain of the toxin binds with high affinity to the plasma membrane of the motor neuron, which allows the light chain to translocate by endocytosis into the nerve. [2][3][4][5] The light chain cleaves the synaptosomalassociated protein . Proteolysis of SNAP-25 prevents fusion of acetylcholine-containing vesicles from binding to the cell membrane, creating a neural blockade.…”

Section: Botulinum Toxinmentioning

confidence: 99%

“…Proteolysis of SNAP-25 prevents fusion of acetylcholine-containing vesicles from binding to the cell membrane, creating a neural blockade. [2][3][4][5] Toxin B acts in a similar manner, but acts on synaptobrevin instead of SNAP-25.…”

Section: Botulinum Toxinmentioning

confidence: 99%

“…These toxins are used to selectively weaken the musculature of the face to decrease tissue contraction and, thus, rhytid formation. [2][3][4] Onset occurs within a few days of injection when the nerve is no longer able to release acetylcholine to the innervated muscle. 5 The effect of the toxin is usually appreciable for 3 to 4 months, but diminishing effects can be apparent for a longer period of time.…”

Section: Botulinum Toxinmentioning

confidence: 99%

See 1 more Smart Citation

Tissue Modification in Nonsurgical Facelift Options

2020

View full text Add to dashboard Cite

Nonsurgical facelifts are a term for a heterogeneous group of procedures used by physicians to improve facial rejuvenation without the use of operative techniques. Patients demand these services due to the reduced recovery time and generally lower risk. However, nonsurgical techniques, to be effective, must induce conformational change in the cells and tissues of the face. Therefore, these techniques are significant procedures that have associated risks. Understanding the tissue modifications and mechanisms of action of these techniques is vital to their safe and effective use. The purpose of this article is to provide a background of tissue modification in nonsurgical facelift options.

show abstract

Comparison of Botulinum Toxins A and B in the Aesthetic Treatment of Facial Rhytides

Cited by 2 publications

References 43 publications

The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review

The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review

Tissue Modification in Nonsurgical Facelift Options

Contact Info

Product

Resources

About